IBIO iBio, Inc.

$1.43

iBio, Inc. (IBIO) is expected to report earnings on September 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.7% since its last earnings release on May 12, 2026.

iBio Missed Consensus Estimates
Tuesday, May 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Jun 2026
Sep 28
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.07)
Rev est $100K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.61

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About iBio, Inc.

Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.

Sector

Healthcare

Industry

Biotechnology